To the full analysis
Buyback calculator for Cytek Biosciences
Cytek Biosciences stock: key metrics
CTKBCytek Biosciences had an operating margin of −20% and a return on invested capital (ROIC) of −26.7% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 12 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2019 | 49.5% | −29.8% | −29.1% |
| 2020 | 55.7% | 14.7% | 20.9% |
| 2021 | 61.9% | 7.2% | 2.3% |
| 2022 | 61.6% | −1.1% | 1.6% |
| 2023 | 56.7% | −14.4% | −6.3% |
| 2024 | 55.4% | −10.2% | −3.0% |
| 2025 | 51.8% | −20.0% | −33.0% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2019 | 40.4% | −27.6% | −23.9% |
| 2020 | −100.0% | 11.1% | 8.8% |
| 2021 | 0.7% | 1.5% | 0.6% |
| 2022 | 0.6% | −2.5% | 0.5% |
| 2023 | −3.1% | −17.8% | −2.5% |
| 2024 | −1.5% | −11.6% | −1.2% |
| 2025 | −19.5% | −26.7% | −14.4% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jan 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.